Mark Smith, Finch Therapeutics CEO

FDA slaps hold on Finch's mi­cro­bio­me C. dif­fi­cile treat­ment, as biotech blames Covid-19 and old man­u­fac­tur­er

Drug­mak­ers work­ing on treat­ments for C. dif­fi­cile in­fec­tions are hav­ing a bad week.

Just one day af­ter Pfiz­er re­port­ed its C. dif­fi­cile vac­cine can­di­date …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.